Key statistics
As of last trade KALA BIO Inc (27F0:DUS) traded at 0.3288, 9.67% above its 52-week low of 0.2998, set on Feb 13, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.3276 |
|---|---|
| High | 0.329 |
| Low | 0.3276 |
| Bid | 0.3288 |
| Offer | 0.3588 |
| Previous close | 0.3178 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 27.85m |
| Free float | 27.78m |
| P/E (TTM) | -- |
| Market cap | 11.32m USD |
| EPS (TTM) | -5.94 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 11:30 GMT.
More ▼
Announcements
- KALA BIO Settles Approximately $10.6 million of Debt
- KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
- KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
- KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
- KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
- KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
- KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
- KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
- KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
More ▼
